Muscle and Neuromuscular Junction Disorders
肌肉和神经肌肉连接障碍
Pub Date : 2011-12-15
DOI: 10.1201/b15187-14
W. Bernard
AAN. See American Academy of Neurology Acetylcholine, 1789, 1978Y1979 Acetylcholine receptor (AChR), 1978Y1979 Acetylcholine receptor (AChR) antibodies in myasthenia gravis, 1979Y1980 babies of mothers with MG, 1981 diagnostic specificity of, 1981, 1988 immunomodulatory treatment and, 1995Y1996 LRP4 antibodies and, 1988 MuSK antibodies and, 1984 myasthenia-myositis overlap, 1865 thymic pathology and, 1981, 1988, 1996 Acetylcholinesterase, 1909, 1914r, 1979, 1992 N-Acetylcysteine, for congenital myopathies, 1940, 1950 AChR. See Acetylcholine receptor Acid maltase deficiency, 1790t, 1893t, 1922, 1968, 1974t, 1975t Acromegaly, 1815, 1816t, 1821, 1826r ACTA1 gene, 1934t, 1937, 1940c, 1942, 1944, 1946, 1950, 1953r !-Actin 1 gene. See ACTA1 gene Acute renal failure, 1833, 1834, 1839, 1866t Acute respiratory distress syndrome, 1822c, 1827r Acylcarnitine profile, 1811 in metabolic myopathies, 1829, 1837, 1839Y1841, 1841c, 1847 Addison disease, 1821 Adenosine diphosphate (ADP), 1804, 1830 Adenosine monophosphate (AMP), 1830 Adenosine triphosphate (ATP), 1804, 1830, 1832, 1845 ADP (adenosine diphosphate), 1804, 1830 Adrenal dysfunction, 1815, 1816t, 1820Y1821 Aerobic exercise intensity, 1831 Agency for Healthcare Research and Quality, 2012 Agency for Toxic Substances and Disease Registry, 2014 Agrin, 1979 Agrin antibodies in myasthenia gravis, 1980, 1981, 1988, 2003r Alanine aminotransferase (ALT) level, 1811 in dermatomyositis, 1792c, 1856 in myasthenia gravis, 1994 Albuterol for core myopathies, 1940, 1952r for facioscapulohumeral muscular dystrophy, 1926, 1931r Alcohol myopathy, 1804t, 1816t, 1826, 1828r Aldolase A deficiency, 1831t, 1833 Alemtuzumab, for inclusion body myositis, 1883, 1885t, 1888r ALS. See Amyotrophic lateral sclerosis ALS Association, 2014 ALT. See Alanine aminotransferase level American Academy of Neurology (AAN) Axoni Registry, 2014, 2014r management guidelines for facioscapulohumeral muscular dystrophy, 1926 Amino acid oxidation defects, 1829 Amiodarone myopathy, 1815, 1816t, 1817t, 1824Y1825, 1827r Ammonia level, in glycogen-storage diseases, 1834c, 1835, 1836, 1837t, 1847 AMP (adenosine monophosphate), 1830 AMPD1 gene, 1835, 1848r Amphiphysin 2 gene. See BIN1 gene Amyloid-" precursor protein, 1878Y1879, 1887r Amyloid deposition, 1799 in inclusion body myositis, 1878, 1882, 1887r in limb-girdle muscular dystrophy, 1964, 1976t Amyotrophic lateral sclerosis (ALS), 1790t, 2010r EMG in, 1986, 1987 vs. inclusion body myositis, 1872, 1879 LRP4 antibodies in, 1988 vs. myasthenia gravis, 1986, 1987, 1990t national registry for, 014r, 2014 VCP-related, 2007, 2008, 2010r Anaerobic threshold, 1831 Angiotensin-converting enzyme inhibitors in dystrophinopathies, 1971 in McArdle disease, 1839 ANO5 gene, 1829, 1848r, 1961t, 1966 Anoctaminopathy (LGMD type 2L), 1961t, 1966, 1974t, 1975t Antidepressants in dystrophinopathies, 1973 in facioscapulohumeral muscular dystrophy, 1927 tricyclic in myotonic dystrophy, 1904, 1907t in nondystrophic myotonia
河畔。参见美国神经病学学会乙酰胆碱，1789年，1978Y1979乙酰胆碱受体(AChR)， 1978Y1979乙酰胆碱受体(AChR)抗体在重症肌无力的母亲，1979Y1980, 1981年诊断特异性，1981年，1988年免疫调节治疗和，1995Y1996 LRP4抗体和，1988年麝香抗体和，1984年重症肌无力-肌炎重叠，1865胸腺病理和，1981年，1988年，1996年乙酰胆碱酯酶，1909年，1914r, 1979年，1992年n -乙酰半胱氨酸，先天性肌病，1940,1950 AChR。参见Acetylcholine receptor Acid maltase deficiency, 1790t, 1893t, 1922, 1968, 1974t, 1975t肢端肥大症，1815,1816t, 1821, 1826r ACTA1基因，1934t, 1937, 1940c, 1942, 1944, 1946, 1950, 1953r -Actin 1基因。参见ACTA1基因，急性肾功能衰竭，1833,1834,1839,1866;急性呼吸窘迫综合征，1822c, 1827r酰基肉碱谱，1811代谢性肌病，1829,1837,1839Y1841, 1841c, 1847 Addison病，1821二磷酸腺苷(ADP)， 1804, 1830单磷酸腺苷(AMP)， 1830三磷酸腺苷(ATP)， 1804, 1830, 1832, 1845 ADP(二磷酸腺苷)，1804,1830,1816t, 1820Y18211831中国卫生保健研究与质量局，2012中国有毒物质与疾病登记局，2014 Agrin, 1979 Agrin抗体在重症肌无力中的作用，1980,1981,1988,1988,2003r丙氨酸转氨酶(ALT)水平，1811在皮肌炎中的作用，1792,1856在重症肌无力中的作用，1994,1952r在面部肩关节肌营养不良中的作用，1940,1952r在酒精性肌病中的作用，1804t, 1816t, 1826,1828r醛缩酶A缺乏症，1831t, 1833阿仑妥单抗，包涵体肌炎，1883年，1885年，1888年或ALS。参见丙氨酸转氨酶水平美国神经病学学会(AAN) Axoni Registry, 2014, 2014r面部肩关节肌营养不良管理指南，1926氨基酸氧化缺陷，1829胺碘酮肌病，1815,1816t, 1817t, 1824y1825,1827r氨水平，糖原储存病，1834c, 1835, 1836, 1837t, 1847 AMP(腺苷单磷酸)，1830 AMPD1基因，1835,1848r Amphiphysin 2基因。参见BIN1基因Amyloid-“前体蛋白，1878y1879,1887r淀粉样蛋白沉积，1799在包涵体肌炎中，1878,1882,1887r在四肢肌萎缩症中，1964,1976;肌萎缩侧索硬化症(ALS)， 1790,2010;肌电图in, 1986, 1987与包涵体肌炎，1872,1879,LRP4抗体in, 1988与重症肌无力，1986,1987,1990;国家登记，014r, 2014 vcp相关，2007,2008,2010;1831血管紧张素转换酶抑制剂在肌营养不良症中的应用，1971在McArdle病中的应用，1839 ANO5基因，1829,1848r, 1961t, 1966在神经性肌营养不良症(LGMD型2L)中的应用，1961t, 196196,1974t, 1975t抗抑郁药在肌营养不良症中的应用，1973在面骨肱肌营养不良症中的应用，1927三环在肌强直性肌营养不良症中的应用，1940,1977t在非营养不良性肌强直症中的应用，1910妊娠期抗癫痫药的应用，2013,2014 r先天性肌病的抗氧化剂，1940,1950,1952r在线粒体肌病中的应用，1846抗逆转录病毒药物诱导的肌病，1816t、1817t、1825,1828r抗合成酶综合征，1857t、1863Y1864、1867c抗包体体肌炎t淋巴细胞球蛋白(ATG)， 1883Y1884、1888r APP基因，1878Y1879、1882t、1887r阿利莫洛尔，包体体肌炎，1885t天冬氨酸转氨酶(AST)水平，1811皮肌炎，1792c、1856重症肌无力，1994 AST.参见天冬氨酸转氨酶水平ATG(抗t淋巴细胞球蛋白)，1883Y1884，1888r * 2016美国神经病学学会。版权所有。
{"title":"Muscle and Neuromuscular Junction Disorders","authors":"W. Bernard","doi":"10.1201/b15187-14","DOIUrl":"https://doi.org/10.1201/b15187-14","url":null,"abstract":"AAN. See American Academy of Neurology Acetylcholine, 1789, 1978Y1979 Acetylcholine receptor (AChR), 1978Y1979 Acetylcholine receptor (AChR) antibodies in myasthenia gravis, 1979Y1980 babies of mothers with MG, 1981 diagnostic specificity of, 1981, 1988 immunomodulatory treatment and, 1995Y1996 LRP4 antibodies and, 1988 MuSK antibodies and, 1984 myasthenia-myositis overlap, 1865 thymic pathology and, 1981, 1988, 1996 Acetylcholinesterase, 1909, 1914r, 1979, 1992 N-Acetylcysteine, for congenital myopathies, 1940, 1950 AChR. See Acetylcholine receptor Acid maltase deficiency, 1790t, 1893t, 1922, 1968, 1974t, 1975t Acromegaly, 1815, 1816t, 1821, 1826r ACTA1 gene, 1934t, 1937, 1940c, 1942, 1944, 1946, 1950, 1953r !-Actin 1 gene. See ACTA1 gene Acute renal failure, 1833, 1834, 1839, 1866t Acute respiratory distress syndrome, 1822c, 1827r Acylcarnitine profile, 1811 in metabolic myopathies, 1829, 1837, 1839Y1841, 1841c, 1847 Addison disease, 1821 Adenosine diphosphate (ADP), 1804, 1830 Adenosine monophosphate (AMP), 1830 Adenosine triphosphate (ATP), 1804, 1830, 1832, 1845 ADP (adenosine diphosphate), 1804, 1830 Adrenal dysfunction, 1815, 1816t, 1820Y1821 Aerobic exercise intensity, 1831 Agency for Healthcare Research and Quality, 2012 Agency for Toxic Substances and Disease Registry, 2014 Agrin, 1979 Agrin antibodies in myasthenia gravis, 1980, 1981, 1988, 2003r Alanine aminotransferase (ALT) level, 1811 in dermatomyositis, 1792c, 1856 in myasthenia gravis, 1994 Albuterol for core myopathies, 1940, 1952r for facioscapulohumeral muscular dystrophy, 1926, 1931r Alcohol myopathy, 1804t, 1816t, 1826, 1828r Aldolase A deficiency, 1831t, 1833 Alemtuzumab, for inclusion body myositis, 1883, 1885t, 1888r ALS. See Amyotrophic lateral sclerosis ALS Association, 2014 ALT. See Alanine aminotransferase level American Academy of Neurology (AAN) Axoni Registry, 2014, 2014r management guidelines for facioscapulohumeral muscular dystrophy, 1926 Amino acid oxidation defects, 1829 Amiodarone myopathy, 1815, 1816t, 1817t, 1824Y1825, 1827r Ammonia level, in glycogen-storage diseases, 1834c, 1835, 1836, 1837t, 1847 AMP (adenosine monophosphate), 1830 AMPD1 gene, 1835, 1848r Amphiphysin 2 gene. See BIN1 gene Amyloid-\" precursor protein, 1878Y1879, 1887r Amyloid deposition, 1799 in inclusion body myositis, 1878, 1882, 1887r in limb-girdle muscular dystrophy, 1964, 1976t Amyotrophic lateral sclerosis (ALS), 1790t, 2010r EMG in, 1986, 1987 vs. inclusion body myositis, 1872, 1879 LRP4 antibodies in, 1988 vs. myasthenia gravis, 1986, 1987, 1990t national registry for, 014r, 2014 VCP-related, 2007, 2008, 2010r Anaerobic threshold, 1831 Angiotensin-converting enzyme inhibitors in dystrophinopathies, 1971 in McArdle disease, 1839 ANO5 gene, 1829, 1848r, 1961t, 1966 Anoctaminopathy (LGMD type 2L), 1961t, 1966, 1974t, 1975t Antidepressants in dystrophinopathies, 1973 in facioscapulohumeral muscular dystrophy, 1927 tricyclic in myotonic dystrophy, 1904, 1907t in nondystrophic myotonia","PeriodicalId":129531,"journal":{"name":"Equine Pediatric Medicine","volume":"145 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130278789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：